

# Avertto

Avertto is an Israeli health-tech startup developing a **subcutaneous AI-powered carotid pulse monitor** designed for **real-time stroke detection**, especially large vessel occlusion (LVO).

## □ Technology

- **Continuous hemodynamic monitoring:** Learns a personalized baseline from long-term carotid pulse data :contentReference[oaicite:1]{index=1}
- **AI-driven detection:** Deep learning + template-matching algorithms identify deviations from baseline :contentReference[oaicite:2]{index=2}
- **Alert & response:** On detecting elevated stroke risk, it sends GPS-enabled alerts to care providers :contentReference[oaicite:3]{index=3}

## □ Clinical Results

- **Balloon occlusion study (n=67):** 100 % sensitivity for LVO at 40 % probability threshold, with zero false positives :contentReference[oaicite:4]{index=4}
- **ICU monitoring (n=10):** All LVOs flagged hours to days before clinical diagnosis, no false alerts :contentReference[oaicite:5]{index=5}

## □ Company Updates

- **IIA funding:**
  - NIS 2.5 M (Oct 2022) for development
  - NIS 5 M (Sept 2023) for multi-center clinical trials :contentReference[oaicite:6]{index=6}
- **Awards:**
  - €75 K EU Women-Tech grant (July 2022)
  - 1st prize, Hebrew University Asper competition (June 2023)
  - Forbes Aviram Awards finalist (May 2023) :contentReference[oaicite:7]{index=7}

## □ Team

- **Dr Hilla Ben-Pazi (CEO)** – Neurologist, former tele-neurology entrepreneur :contentReference[oaicite:8]{index=8}
- **Yaniv Kirma (CTO)** – 25+ years in MedTech & defense engineering :contentReference[oaicite:9]{index=9}
- **Ilana Zigelman (QA/Regulatory Lead)** – Ex-FDA investigator :contentReference[oaicite:10]{index=10}
- **Yair Lavi (AI/Signal Processing)** – Startup AI specialist :contentReference[oaicite:11]{index=11}

## □ Strategic Roadmap

- **AMIT301 Class I device** on track:
  - Q1 2025: US & Israel Class-I registration :contentReference[oaicite:12]{index=12}
  - Q3 2025: Planned first sales deployment :contentReference[oaicite:13]{index=13}
- **Global clinical footprint:** trials in Israel, Spain, USA; ICU and balloon-occlusion studies completed; astronaut (microgravity) study in collaboration with Axiom Space :contentReference[oaicite:14]{index=14}

## □ Context & Vision

- Avertto aims to extend continuous cerebrovascular monitoring across ICU and home settings, shifting stroke care from reactive to proactive :contentReference[oaicite:15]{index=15}
- Positioned as the first insertable AI-based stroke alert device, targeting a global market of ~120 M at-risk patients annually :contentReference[oaicite:16]{index=16}

## □ References

- \*Israel21c\*, "Swift stroke prevention using AI and artery monitors," Oct 15 2024 :contentReference[oaicite:17]{index=17}
- \*PubMed Frontiers in Neurology\*, "Pre-hospital stroke monitoring...", 2024 :contentReference[oaicite:18]{index=18}
- LinkedIn update by Hilla Ben-Pazi on device milestone schedule :contentReference[oaicite:19]{index=19}

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=avertto>

Last update: **2025/07/02 06:26**

